The 3-year renal safety of a tenofovir disoproxil furnarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients

被引:87
作者
Gallant, Joel E. [2 ]
Winston, Jonathan A. [3 ]
Dejesus, Edwin [4 ]
Pozniak, Anton L. [5 ]
Chen, Shan-Shan [1 ]
Cheng, Andrew K. [1 ]
Enejosa, Jeffrey V. [1 ]
机构
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Orlando Immunol Ctr, Orlando, FL USA
[5] Chelsea & Westminster Hosp, London, England
关键词
kidney; renal safety; tenofovir disoproxil fumarate; thymidine analogue; treatment-naive;
D O I
10.1097/QAD.0b013e3283112b8e
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Cases of renal dysfunction in patients receiving tenofovir disoproxil fumarate (TDF) have been reported. We analyzed the renal safety of TDF compared with thymidine analogue-containing (control) regimens through 144 weeks from two clinical trials in anti retroviral-naive HIV-infected patients. Methods: We evaluated the changes in renal parameters in 1111 patients (TDF, n=556; control, n=555) who were enrolled in two randomized, controlled trials (Studies 903 and 934) comparing TDF vs. either stavudine or zidovudine in combination with efavirenz and either lamivudine or emtricitabine. The studies included patients with serum creatinine less than 1.5 mg/dl, serum phosphorus at least 2.2 mg/dl and estimated glomerular filtration rate by Cockcroft-Gault at least 60 and at least 50 ml/min at screening. Results: Baseline characteristics were similar between groups. No patient discontinued due to renal abnormalities in the TDF arm. Through 144 weeks, the proportion of patients who experienced confirmed abnormalities in serum creatinine (>1.5 mg/dl) or serum phosphorus (<2.0 mg/dl) was less than 1% in both groups; a similar proportion of patients experienced urine proteinuria at least 100 mg/dl (TDF, 5%; control, 6%). The median change from baseline to week 144 in glomerular filtration rate was -2 and 3 ml/min by Cockcroft-Gault, and -2 and -1 ml/min per 1.73 m(2) by modification of diet in renal disease in the TDF and control groups (P < 0.05), respectively. Conclusion: In two randomized, controlled trials, small differences in glomerular filtration rate over time were noted but no clinically relevant renal disease or adverse events were demonstrated in antiretroviral-naive patients treated with TDF through 144 weeks. Additional studies on renal health and renal safety in HIV are important goals for future clinical trials. (C) 2008 Wolters Kluwer Health / Lippincott Williams & Wilkins
引用
收藏
页码:2155 / 2163
页数:9
相关论文
共 35 条
[1]   Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis [J].
Arribas, Jose R. ;
Pozniak, Anton L. ;
Gallant, Joel E. ;
DeJesus, Edwin ;
Gazzard, Brian ;
Campo, Rafael E. ;
Chen, Shan-Shan ;
McColl, Damian ;
Holmes, Charles B. ;
Enejosa, Jeffrey ;
Toole, John J. ;
Cheng, Andrew K. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (01) :74-78
[2]   Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs [J].
Cihlar, T ;
Ho, ES ;
Lin, DC ;
Mulato, AS .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7) :641-648
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]   Renal lesions in HIV-1-positive patient treated with tenofovir [J].
Créput, C ;
Gonzalez-Canali, G ;
Hill, G ;
Piketty, C ;
Kazatchkine, M ;
Nochy, D .
AIDS, 2003, 17 (06) :935-937
[5]  
DEJESUS E, 2007, 47 ANN INT C ANT AG
[6]  
*FDA ANT DRUG PROD, 2001, P FDA ANT DURG PROD
[7]   Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment [J].
Gallant, JE ;
Parish, MA ;
Keruly, JC ;
Moore, RD .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (08) :1194-1198
[8]   Tenofovir and changes in renal function - Reply to Gupta [J].
Gallant, JE ;
Parish, MA ;
Keruly, JC ;
Moore, RD .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (04) :571-571
[9]   Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial [J].
Gallant, JE ;
Staszewski, S ;
Pozniak, AL ;
DeJesus, E ;
Suleiman, JMAH ;
Miller, MD ;
Coakley, DF ;
Lu, B ;
Toole, JJ ;
Cheng, AK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :191-201
[10]   No change in calculated creatinine clearance after tenofovir initiation among Thai patients [J].
Gayet-Ageron, Angele ;
Ananworanich, Jintanat ;
Jupimai, Thidarat ;
Chetchotisakd, Ploenchan ;
Prasithsirikul, Wisit ;
Ubolyam, Sasiwimol ;
Le Braz, Michelle ;
Ruxrungtham, Kiat ;
Rooney, James F. ;
Hirschel, Bernard .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (05) :1034-1037